Visual Abstract
Background: The SWITCH PRO trial demonstrated increased time in range (TIR) with insulin degludec vs. insulin glargine U100 in basal insulin-treated type 2 diabetes (T2D). This post hoc analysis of SWITCH PRO evaluated correlation of change in TIR with change in A1C during the trial.
Methods: Correlation between change in TIR (70-180 mg/dL) and change in A1C from baseline (BL) to end of Maintenance 1 in the full cohort or subgroups stratified by BL median A1C (<7.5% or ≥7.5%) was assessed using Spearman correlation coefficient (rs).
Results: BL characteristics between subgroups were similar. A linear correlation between change in TIR and change in A1C was demonstrated (Figure) in the full (rs -0.400) and BL A1C ≥7.5% (rs -0.426) subgroups, but this was less apparent in the BL A1C <7.5% subgroup (rs -0.173) (interaction p = 0.07). Increase in TIR equated to the greatest decrease in A1C in the BL A1C ≥7.5% subgroup: a 5% increase in TIR corresponded to estimated decreases in A1C of -0.4%, -0.1% and -0.7% in full, BL A1C <7.5% and BL A1C ≥7.5% subgroups, respectively; and a 10% increase in TIR to estimated A1C decreases of -0.5%, -0.1% and -0.8%, respectively.
Discussion: Change in TIR was associated with change in A1C in this basal insulin-treated population, with closer association at higher baseline A1C. Change in TIR may offer complementary insights to change in A1C in measuring response to therapy.
R. Goldenberg: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Consultant; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Research Support; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Canada Inc., Sanofi, Speaker's Bureau; Self; Agora , Amgen Canada, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., CCRN, CHRC, CMS Canada, CSEM, Eli Lilly and Company, EOCI , HLS Therapeutics Inc., Inceptus, Janssen Pharmaceuticals, Inc., liV Medical Education Agency, Master Clinician Alliance , Medplan, Merck & Co., Inc., Mylan N. V., Novo Nordisk Canada Inc., Sanofi, Servier Laboratories, STA Communications Inc., TKTWG, Valeant . V. R. Aroda: Consultant; Self; Applied Therapeutics, Duke, Novo Nordisk, Pfizer Inc., Sanofi, Employee; Spouse/Partner; Janssen , Merck , Research Support; Self; Applied Therapeutics, Eli Lilly and Company, Fractyl , Medpace, Medpace, Novo Nordisk, Premier , Sanofi, Stock/Shareholder; Spouse/Partner; Janssen, Merck. L. K. Billings: Advisory Panel; Self; Bayer Inc., Lilly Diabetes, Novo Nordisk, Sanofi. A. Meller donatsky: Employee; Self; Novo Nordisk A/S. M. Frederiksen: Employee; Self; Novo Nordisk A/S. D. C. Klonoff: Consultant; Self; EOFlow, Fractyl Laboratories, Inc., LifeCare, Inc., Novo Nordisk, Roche Diagnostic USA, Samsung, Thirdwayv, Employee; Self; DIabetes Technology Society. E. Parvaresh rizi: Employee; Self; Novo Nordisk. R. M. Bergenstal: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk, Onduo LLC., Roche , Sanofi, United Healthcare , Consultant; Self; Abbott Diabetes, Ascensia , Dexcom, Inc., Eli Lilly and Company, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Other Relationship; Self; HealthPartners Institute, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, NIDDK, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare.
Novo Nordisk A/S